Sanofi

Praluent (alirocumab) is a PCSK9 inhibitor from Sanofi and Regeneron. By blocking PCSK9, it preserves LDL receptors on liver cells, sharply lowering LDL cholesterol and reducing major cardiovascular events in adults at increased risk.

LDL cholesterol is removed from the blood by receptors on liver cells. A protein called PCSK9 causes those receptors to be broken down, limiting how m

Plavix (clopidogrel) is a P2Y12 platelet inhibitor from Sanofi that prevents platelets from clumping into clots. It reduces the risk of heart attack and stroke after acute coronary syndromes, recent myocardial infarction, recent stroke, or established peripheral arterial disease.

Clopidogrel belongs to the antiplatelet class. After it is taken by mouth, the body converts it into an active form that permanently blocks the P2Y12

Dupixent (dupilumab) is a monoclonal antibody from Sanofi that blocks interleukin-4 and interleukin-13 signalling, two drivers of type 2 inflammation. It is used in moderate-to-severe atopic dermatitis, and as add-on therapy in selected asthma.

Atopic dermatitis and some forms of asthma are fuelled by type 2 inflammation, in which the immune signals IL-4 and IL-13 keep tissues irritated. Dupi

Lantus (insulin glargine) is a long-acting basal insulin from Sanofi. A single daily injection provides a steady, peakless insulin level for about 24 hours, controlling blood sugar in type 1 diabetes and in type 2 diabetes when other medicines are not enough.

Insulin is the hormone that lets cells absorb glucose from the blood. People with type 1 diabetes make none, and many with type 2 diabetes eventually

Isatuximab (Sarclisa) is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells. It helps the immune system recognize and destroy those cancer cells. It is used in combination with other medicines to treat multiple myeloma.

Isatuximab is a monoclonal antibody, which means it is a laboratory-made protein designed to find and attach to a specific target. In this case, it ta